Published in PLoS One on April 29, 2015
Effect of Sofosbuvir-Based Hepatitis C Virus Therapy on Kidney Function in Patients with CKD. Clin J Am Soc Nephrol (2017) 0.79
Interferon-free regimens in patients with hepatitis C infection and renal dysfunction or kidney transplantation. World J Hepatol (2017) 0.75
A new equation to estimate glomerular filtration rate. Ann Intern Med (2009) 71.41
Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care (2007) 29.89
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Telaprevir for retreatment of HCV infection. N Engl J Med (2011) 10.48
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med (2009) 10.21
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (2011) 8.95
Telaprevir for previously treated chronic HCV infection. N Engl J Med (2010) 8.33
Acute kidney injury increases risk of ESRD among elderly. J Am Soc Nephrol (2008) 6.91
Dialysis-requiring acute renal failure increases the risk of progressive chronic kidney disease. Kidney Int (2009) 5.28
Renal failure in cirrhosis. N Engl J Med (2009) 4.46
Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir. Hepatology (2013) 3.68
Outcomes following diagnosis of acute renal failure in U.S. veterans: focus on acute tubular necrosis. Kidney Int (2009) 2.52
Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol (2011) 2.18
Antiviral therapy for hepatitis C virus--associated mixed cryoglobulinemia vasculitis: a long-term followup study. Arthritis Rheum (2006) 2.09
Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. Hepatology (2014) 2.04
Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease. J Am Soc Nephrol (2005) 1.94
Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C. J Viral Hepat (2014) 1.54
Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease. Arch Intern Med (2007) 1.45
Telaprevir-induced acute kidney injury during treatment of chronic hepatitis C. Eur J Gastroenterol Hepatol (2014) 1.42
Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET. J Hepatol (2014) 1.36
Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology (2014) 1.27
Interaction of the antiviral drug telaprevir with renal and hepatic drug transporters. Biochem Pharmacol (2012) 1.06
Telaprevir-related dermatitis. JAMA Dermatol (2013) 0.98
Comorbid diabetes and the risk of progressive chronic kidney disease in HIV-infected adults: data from the Veterans Aging Cohort Study. J Acquir Immune Defic Syndr (2012) 0.98
Association of hepatitis C virus infection with risk of ESRD: a population-based study. Am J Kidney Dis (2012) 0.94
Serum creatinine changes associated with critical illness and detection of persistent renal dysfunction after AKI. Clin J Am Soc Nephrol (2014) 0.94
Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis. PLoS One (2014) 0.90
Boceprevir and telaprevir-based triple therapy for chronic hepatitis C: virological efficacy and impact on kidney function and model for end-stage liver disease score. J Viral Hepat (2014) 0.85
Acute renal failure and liver toxicity in an HIV/hepatitis C coinfected patient receiving telaprevir and boosted atazanavir. AIDS (2014) 0.83
eGFR decrease during antiviral C therapy with first generation protease inhibitors: a clinical significance? Liver Int (2014) 0.79
Telaprevir therapy, renal impairment, and their effects on the pharmacokinetics of tenofovir in HIV/hepatitis C virus coinfected patients. AIDS (2014) 0.79
Reply to: Telaprevir-induced acute kidney injury during treatment of chronic hepatitis C. Eur J Gastroenterol Hepatol (2014) 0.77